| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1033389861 |
| P356 | DOI | 10.1046/J.1523-1747.2000.00996.X |
| P698 | PubMed publication ID | 10844558 |
| P5875 | ResearchGate publication ID | 232757582 |
| P2093 | author name string | Taïeb A | |
| Orth G | |||
| Favre M | |||
| Rueda LA | |||
| Bouadjar B | |||
| Ramoz N | |||
| Montoya LS | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | susceptibility locus | Q62091149 |
| epidermodysplasia verruciformis | Q974691 | ||
| P304 | page(s) | 1148-1153 | |
| P577 | publication date | 2000-06-01 | |
| P1433 | published in | Journal of Investigative Dermatology | Q3186921 |
| P1476 | title | Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. | |
| P478 | volume | 114 |
| Q45271493 | A 6-Mb contig-based comparative gene and linkage map of the rat schwannoma tumor suppressor region at 10q32.3. |
| Q35906877 | Acquired epidermodysplasia verruciformis due to multiple and unusual HPV infection among vertically-infected, HIV-positive adolescents in Zimbabwe. |
| Q46535189 | An unusual presentation of human papillomavirus (HPV) infection in a black epidermodysplasia verruciformis (EV) patient |
| Q44786549 | Association of p53 arginine polymorphism with skin cancer |
| Q36099622 | Autosomal dominant epidermodysplasia verruciformis lacking a known EVER1 or EVER2 mutation |
| Q36803778 | Beta-papillomaviruses and psoriasis: an intra-patient comparison of human papillomavirus carriage in skin and hair |
| Q36489770 | Contribution of TMC6 and TMC8 (EVER1 and EVER2) variants to cervical cancer susceptibility |
| Q24653979 | Cutaneous human papillomavirus infection, the EVER2 gene and incidence of squamous cell carcinoma: a case-control study |
| Q44206123 | Detection of Merkel cell polyomavirus in epidermodysplasia-verruciformis-associated skin neoplasms. |
| Q34326712 | EVER proteins, key elements of the natural anti-human papillomavirus barrier, are regulated upon T-cell activation |
| Q55346681 | Epidermodysplasia Verruciformis: Inborn Errors of Immunity to Human Beta-Papillomaviruses. |
| Q73268341 | Epidermodysplasia verruciformis in a patient with HIV infection: no response to highly active antiretroviral therapy |
| Q44604985 | Epidermodysplasia verruciformis with multiple mucosal carcinomas treated with pegylated interferon alfa and acitretin |
| Q79276588 | Epidermodysplasia verruciformis: A model of virus-caused oncogenesis in the skin |
| Q39948929 | Epidermodysplasia verruciformis: An early and unusual presentation. |
| Q46921428 | Epidermodysplasia verruciformis: unsuccessful therapeutic approach with imiquimod |
| Q44655808 | Homozygosity for the c.917A→T (p.N306l) polymorphism in the EVER2/TMC8 gene of two sisters with epidermodysplasia verruciformis Lewandowsky-Lutz originally described by Wilhelm Lutz |
| Q38240647 | Human Beta-papillomavirus infection and keratinocyte carcinomas |
| Q29027555 | Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections |
| Q54635530 | Human papillomavirus type 5 in primary keratinocytes from psoriatic skin. |
| Q35915935 | Mechanisms of human papillomavirus-induced oncogenesis. |
| Q37133594 | Molecular epidemiology of human papillomavirus |
| Q24317519 | Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis |
| Q55044352 | Novel homozygous nonsense TMC8 mutation detected in patients with epidermodysplasia verruciformis from a Brazilian family. |
| Q37316158 | Oncogenic activities of human papillomaviruses |
| Q58766185 | Oral manifestations of human papillomavirus infections |
| Q35398350 | Papillomavirus research update: highlights of the Barcelona HPV 2000 international papillomavirus conference |
| Q44575794 | Possible involvement of epidermodysplasia verruciformis human papillomaviruses in the immunopathogenesis of psoriasis: a proposed hypothesis |
| Q90746855 | Recent advances in primary immunodeficiency: from molecular diagnosis to treatment |
| Q24304914 | Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses |
| Q34998616 | Risk of squamous cell skin cancer after organ transplant associated with antibodies to cutaneous papillomaviruses, polyomaviruses, and TMC6/8 (EVER1/2) variants |
| Q24656940 | Role of Zn2+ ions in host-virus interactions |
| Q53304618 | Seroreactivity of 38 human papillomavirus types in epidermodysplasia verruciformis patients, relatives, and controls. |
| Q26747402 | The EVER genes - the genetic etiology of carcinogenesis in epidermodysplasia verruciformis and a possible role in non-epidermodysplasia verruciformis patients |
| Q37232535 | The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections |
| Q37359553 | The sero-epidemiology of human papillomavirus among Caucasian transplant recipients in the UK. |
| Q33553561 | The transmembrane channel-like protein family and human papillomaviruses: Insights into epidermodysplasia verruciformis and progression to squamous cell carcinoma |
| Q37854816 | Viral oncogenesis and its role in nonmelanoma skin cancer |
| Q53368995 | Why epidermodysplasia verruciformis - a rare genetic disease - has raised such great interest. |
| Q50034017 | Zinc and Skin Disorders. |
| Q60907515 | Zinc in Keratinocytes and Langerhans Cells: Relevance to the Epidermal Homeostasis |
| Q80287298 | [Classification and diagnosis of immunodeficiency syndromes] |
| Q50481173 | [Epidermodysplasia verruciformis]. |
| Q53326527 | [HPV and skin neoplasia]. |
Search more.